Abstract:Objective: Hemangiomas are the most common benign vascular tumors of infancy. Although most infantile hemangiomas (IHs) have the ability to involute spontaneously after initial proliferation and resolve without consequence, intervention is required in a subset of IHs, which develop complications resulting in ulceration, bleeding, or aesthetic deformity. The primary treatment for this subset of IHs is pharmacological intervention, and propranolol has become the new first-line treatment for complicated hemangiomas. Here, we evaluated the efficacy of propranolol on proliferation IH in a clinical cohort including 578 patients.Methods: We retrospectively reviewed a total of 578 IH patients who were treated with oral propranolol from January 2010 to December 2012. Responses to the propranolol treatment were graded as: excellent, good, poor, or no response. Based on the response to propranolol treatment (once daily at a dose of 1.0 mg/kg for patients younger than 2 months; twice daily at daily total dose of 2 mg/kg for patients older than 2 months), additional pharmacotherapies or surgery were used for IH patients for satisfactory clinical outcome.Results: Five hundred and sixty (96.9%) of 578 IH patients in our study responded to oral propranolol treatment, and the response rate was significantly different for different ages of patients (P<0.05), with the youngest patients having the highest response rate. The mean time of treatment was 6 months (range, 3-12 months). For example, response rate to propranolol was 98.1% in patients younger than 2 months, compared with 93.3% in patients older than 2 months and younger than 8 months, and 73.7% in patients older than 8 months. One hundred and thirty one patients who exhibited incompletely involuted hemangiomas were further treated with timolol maleate (n=89) or pulsed dye laser (n=42). One hundred and seventeen (89.3%) of 131 patients showed a positive response. There were no instances of life-threatening complications after propranolol. However, minor side effects were observed including 10 (1.73%) cases of sleep disturbance, 7 (1.21%) cases of diarrhea, and 5 (0.86%) cases of bronchospasm.Conclusion: IH requires early intervention. During the involution phase, tapering propranolol dosage can be done to minimize side effects before discontinuing treatment. For patients exhibiting telangiectasia and chromatosis after propranolol treatment, administration of a 0.5% solution of timolol maleate or pulse dye laser is an effective therapeutic approach for complete involution.

Propranolol Inhibits Angiogenesis Via Down-Regulating the Expression of Vascular Endothelial Growth Factor in Hemangioma Derived Stem Cell

Propranolol Induces Regression of Hemangioma Cells Via the Down-Regulation of the Pi3k/Akt/Enos/Vegf Pathway

Effect of propranolol on apoptosis and VEGF, bFGF expression of hemangioma-derived stem cells

Propranolol represses infantile hemangioma cell growth through the β2-adrenergic receptor in a HIF-1α-dependent manner.

R(+) Propranolol decreases lipid accumulation in hemangioma-derived stem cells

Propranolol Inhibits Endothelial Progenitor Cell Homing: a Possible Treatment Mechanism of Infantile Hemangioma.

Research of the mechanisms of propranolol in the treatment of hemangiomas

Propranolol inhibits stemness of hemangioma through Jagged1

Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies

Pigment Epithelium-Derived Factor/vascular Endothelial Growth Factor Ratio Plays a Crucial Role in the Spontaneous Regression of Infant Hemangioma and in the Therapeutic Effect of Propranolol.

Clinical Efficacy and Therapeutic Mechanisms of Propranolol for Infancy Hemangiomas: an Update

Propranolol inhibits the angiogenic capacity of hemangioma endothelia via blocking β-adrenoceptor in mast cell

Induction of apoptosis in infantile hemangioma endothelial cells by propranolol.

The Use of Propranolol in the Treatment of Infantile Haemangiomas: an Update on Potential Mechanisms of Action

Serum-Level Changes of Vascular Endothelial Growth Factor in Children with Infantile Hemangioma after Oral Propranolol Therapy

Downregulation of Mir-382 by Propranolol Inhibits the Progression of Infantile Hemangioma Via the PTEN-mediated AKT/mTOR Pathway.

Role of Thrombospondin-1 and Nuclear Factor-κB Signaling Pathways in Antiangiogenesis of Infantile Hemangioma

Combinative effects of β -elemene and propranolol on the proliferation, migration, and angiogenesis of hemangioma

Apelin Receptor Can Act As a Specific Marker and Promising Therapeutic Target for Infantile Hemangioma

[Effects of Propranolol on Proliferation of Hemangioma-Derived Mesenchymal Stem Cells ].

Propranolol Therapy for Infantile Hemangioma: Our Experience